Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.073 | 0.7 |
mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.021 | 0.7 |
mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.7 |
mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.7 |
mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.022 | 0.7 |
mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.7 |
mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |